Antitumor activity of suramin in hormone‐refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables

Cancer

Volumn 76, Issue 3, 1995, Pages 453-462

  Dawson, Nancy A ^a,b   Cooper, Michael R ^a,c   Figg, William D ^a   Headlee, Donna J ^a   Thibault, Alain ^a   Bergan, Raymond C ^a   Steinberg, Seth M ^a   Sausville, Edward A ^a   Myers, Charles E ^a,c   Sartor, Oliver ^a,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^d LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

flutamide; hydrocortisone; prostate specific antigen; prostatic neoplasms; suramin

Indexed keywords

FLUTAMIDE; HYDROCORTISONE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; SURAMIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPERGLYCEMIA; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; ORCHIECTOMY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER;

AGED; ANTINEOPLASTIC AGENTS; FLUTAMIDE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURAMIN; TREATMENT FAILURE;

EID: 0029078689     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19950801)76:3<453::AID-CNCR2820760316>3.0.CO;2-E     Document Type: Article

References (43)

1. Suramin: with special reference to onchocerciasis
2. Suramin: a potent inhibitor of reverse transcriptase of RNA tumor viruses
3. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR‐2B cells
4. Suramin binds to platelet derived growth factor and inhibits its activity
5. Transformation of NIH/3T3 cells with basic fibroblast growth factor or the hst/K‐fgf oncogene causes down regulation of the fibroblast growth factor receptor: reversal by suramin
6. Platelet derived growth factors receptors form a high affinity state in membrane preparations
7. Growth factors and cancer
8. Heparin‐binding growth factors and prostate cancer
9. Differences in responsiveness of clonally derived AXC/SSH rat prostate cancer cells to secreted or prototypic mitogens
10. Effect of suramin on human prostate cancer cells in vitro
11. Degeneration of the adrenal cortex produced by germanin
12. Suramin and function of the adrenal cortex [letter]
13. A re‐evaluation of non‐hormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma
14. Chemotherapy for prostate cancer
15. Suramin: an anticancer drug with a unique mechanism of action
16. Suramin: a novel growth factor antagonist with activity in hormone‐refractory metastatic prostate cancer
17. Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation
18. Suramin keratopathy
19. Suramin induced polyneuropathy
20. Suramin in hormone resistant prostate cancer: significant activity but unanticipated toxicity [abstract]
21. Suramin for prostate cancer: a phase I/II study in advanced extensively pretreated disease
22. uramin: here to stay!?
23. Suramin, an active drug for prostate cancer: interim observations in a phase I trial
24. Adaptive control with feedback strategies for suramin dosing
25. Use of adaptive control with feedback to individualize suramin dosing
26. Suramin: development of a population pharmacokinetic model and its use with short intermittent infusions to control plasma drug concentration in patients with prostate cancer
27. Treatment of metastatic prostate cancer with low‐dose prednisone: evaluation of pain and quality of life as pragmatic indices of response
28. Suramin and prostate cancer: the role of hydrocortisone [letter]
29. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone‐refractory metastatic prostate cancer
30. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy
31. Prostate specific antigen decline after antiandrogen withdrawal
32. Flutamide withdrawal syndrome: Its impact on clinical trials in hormone‐refractory prostate cancer
33. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of “hormone‐refractory” prostate cancer
34. A rapid isocratic HPLC assay of suramin in human plasma
35. Prostate‐specific antigen as a measure of disease outcome in metastatic hormone‐refractory prostate cancer
36. Non‐parametric estimation from incomplete observations
37. Evaluation of survival data and two new rank order statistics arising in its consideration
38. Suramin: an old compound with a new biology. PPO updates
39. The contribution of hydrocortisone to the observed response proportions of suramin [abstract]
40. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers
41. Adrenal androgens predict for early progression to flutamide withdrawal in patients with androgen‐independent prostate carcinoma [abstract]
42. The inhibition of humansteroidogenic enzyme activities by suramin